Literature DB >> 23418018

Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Daniel M Green1, Larry E Kun, Katherine K Matthay, Anna T Meadows, William H Meyer, Paul A Meyers, Sheri L Spunt, Leslie L Robison, Melissa M Hudson.   

Abstract

Children with solid tumors, most of which are malignant, have an excellent prognosis when treated on contemporary regimens. These regimens, which incorporate chemotherapeutic agents and treatment modalities used for many decades, have evolved to improve relapse-free survival and reduce long-term toxicity. This review discusses the evolution of the treatment regimens employed for management of the most common solid tumors, emphasizing the similarities between contemporary and historical regimens. These similarities allow the use of historical patient cohorts to identify the late effects of successful therapy and to evaluate remedial interventions for these adverse effects.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23418018      PMCID: PMC3810072          DOI: 10.1002/pbc.24487

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  142 in total

1.  Evaluation of a high dose cyclophosphamide regimen in childhood tumors.

Authors:  J Z Finklestein; R E Hittle; G D Hammond
Journal:  Cancer       Date:  1969-05       Impact factor: 6.860

2.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

3.  Late effects of pelvic rhabdomyosarcoma and its treatment in female survivors.

Authors:  Sheri L Spunt; Teresa A Sweeney; Melissa M Hudson; Catherine A Billups; Matthew J Krasin; Allison L Hester
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

4.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

5.  cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.

Authors:  J J Ochs; A I Freeman; H O Douglass; D S Higby; E R Mindell; L F Sinks
Journal:  Cancer Treat Rep       Date:  1978-02

6.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  Moyamoya phenomenon after radiation for optic glioma.

Authors:  J R Kestle; H J Hoffman; A R Mock
Journal:  J Neurosurg       Date:  1993-07       Impact factor: 5.115

8.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

9.  Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Authors:  Katherine K Matthay; Gregory Yanik; Julia Messina; Alekist Quach; John Huberty; Su-Chun Cheng; Janet Veatch; Robert Goldsby; Patricia Brophy; Leslie S Kersun; Randall A Hawkins; John M Maris
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

10.  Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study.

Authors:  M E Nesbit; C A Perez; M Tefft; E O Burgert; T J Vietti; J Kissane; D J Pritchard; E A Gehan
Journal:  Natl Cancer Inst Monogr       Date:  1981-04
View more
  41 in total

1.  Impact of treatment exposures on cardiovascular risk and insulin resistance in childhood cancer survivors.

Authors:  K Scott Baker; Eric J Chow; Pamela J Goodman; Wendy M Leisenring; Andrew C Dietz; Joanna L Perkins; Lisa Chow; Alan Sinaiko; Antoinette Moran; Anna Petryk; Julia Steinberger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-05       Impact factor: 4.254

2.  Chronic Health Conditions and Neurocognitive Function in Aging Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study.

Authors:  Yin Ting Cheung; Tara M Brinkman; Chenghong Li; Yasmin Mzayek; Deokumar Srivastava; Kirsten K Ness; Sunita K Patel; Rebecca M Howell; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

3.  Neurologic disorders in 4858 survivors of central nervous system tumors in childhood-an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

Authors:  Line Kenborg; Jeanette Falck Winther; Karen Markussen Linnet; Anja Krøyer; Vanna Albieri; Anna Sällfors Holmqvist; Laufey Tryggvadottir; Laura Maria Madanat-Harjuoja; Marilyn Stovall; Henrik Hasle; Jørgen H Olsen
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

Review 4.  Frailty in childhood cancer survivors.

Authors:  Kirsten K Ness; Gregory T Armstrong; Mondira Kundu; Carmen L Wilson; Tamara Tchkonia; James L Kirkland
Journal:  Cancer       Date:  2014-12-19       Impact factor: 6.860

Review 5.  A systematic review of selected musculoskeletal late effects in survivors of childhood cancer.

Authors:  Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Karen Wasilewski-Masker; Louis S Constine; Leslie L Robison; Kirsten K Ness
Journal:  Curr Pediatr Rev       Date:  2014

6.  Age-dependent changes in health status in the Childhood Cancer Survivor cohort.

Authors:  Melissa M Hudson; Kevin C Oeffinger; Kendra Jones; Tara M Brinkman; Kevin R Krull; Daniel A Mulrooney; Ann Mertens; Sharon M Castellino; Jacqueline Casillas; James G Gurney; Paul C Nathan; Wendy Leisenring; Leslie L Robison; Kirsten K Ness
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

7.  Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015.

Authors:  Lucie M Turcotte; Qi Liu; Yutaka Yasui; Michael A Arnold; Sue Hammond; Rebecca M Howell; Susan A Smith; Rita E Weathers; Tara O Henderson; Todd M Gibson; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Joseph P Neglia
Journal:  JAMA       Date:  2017-02-28       Impact factor: 56.272

8.  Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors.

Authors:  Kelly Klega; Alma Imamovic-Tuco; Gavin Ha; Andrea N Clapp; Stephanie Meyer; Abigail Ward; Catherine Clinton; Anwesha Nag; Eliezer Van Allen; Elizabeth Mullen; Steven G DuBois; Katherine Janeway; Matthew Meyerson; Aaron R Thorner; Brian D Crompton
Journal:  JCO Precis Oncol       Date:  2018-07-05

9.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.

Authors:  Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

10.  Parental Considerations Regarding Cure and Late Effects for Children With Cancer.

Authors:  Katie A Greenzang; Hasan Al-Sayegh; Clement Ma; Mehdi Najafzadeh; Eve Wittenberg; Jennifer W Mack
Journal:  Pediatrics       Date:  2020-04-13       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.